Stan Berenshteyn
Stock Analyst at Wells Fargo
(1.14)
# 3,835
Out of 5,182 analysts
87
Total ratings
34.62%
Success rate
-13.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stan Berenshteyn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OMCL Omnicell | Maintains: Overweight | $52 → $55 | $43.44 | +26.61% | 19 | Apr 23, 2026 | |
| PHR Phreesia | Maintains: Overweight | $30 → $25 | $9.67 | +158.53% | 2 | Mar 26, 2026 | |
| CTEV Claritev | Maintains: Equal-Weight | $30 → $22 | $25.31 | -13.08% | 3 | Mar 19, 2026 | |
| HCAT Health Catalyst | Downgrades: Equal-Weight | $5 → $1 | $1.57 | -36.31% | 8 | Mar 18, 2026 | |
| VEEV Veeva Systems | Maintains: Overweight | $333 → $317 | $170.22 | +86.23% | 10 | Mar 5, 2026 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $7 → $3.5 | $2.50 | +40.00% | 9 | Mar 4, 2026 | |
| TDOC Teladoc Health | Maintains: Equal-Weight | $8 → $6 | $6.63 | -9.50% | 4 | Feb 26, 2026 | |
| WAY Waystar Holding | Maintains: Overweight | $41 → $36 | $20.88 | +72.41% | 2 | Feb 19, 2026 | |
| DOCS Doximity | Maintains: Overweight | $55 → $45 | $24.89 | +80.80% | 14 | Feb 6, 2026 | |
| HNGE Hinge Health | Initiates: Overweight | $68 | $48.89 | +39.09% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $17 | $15.72 | +8.14% | 1 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $9 | $6.42 | +40.19% | 5 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $125 | $82.18 | +52.11% | 9 | Feb 26, 2025 |
Omnicell
Apr 23, 2026
Maintains: Overweight
Price Target: $52 → $55
Current: $43.44
Upside: +26.61%
Phreesia
Mar 26, 2026
Maintains: Overweight
Price Target: $30 → $25
Current: $9.67
Upside: +158.53%
Claritev
Mar 19, 2026
Maintains: Equal-Weight
Price Target: $30 → $22
Current: $25.31
Upside: -13.08%
Health Catalyst
Mar 18, 2026
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $1.57
Upside: -36.31%
Veeva Systems
Mar 5, 2026
Maintains: Overweight
Price Target: $333 → $317
Current: $170.22
Upside: +86.23%
GoodRx Holdings
Mar 4, 2026
Maintains: Overweight
Price Target: $7 → $3.5
Current: $2.50
Upside: +40.00%
Teladoc Health
Feb 26, 2026
Maintains: Equal-Weight
Price Target: $8 → $6
Current: $6.63
Upside: -9.50%
Waystar Holding
Feb 19, 2026
Maintains: Overweight
Price Target: $41 → $36
Current: $20.88
Upside: +72.41%
Doximity
Feb 6, 2026
Maintains: Overweight
Price Target: $55 → $45
Current: $24.89
Upside: +80.80%
Hinge Health
Jan 9, 2026
Initiates: Overweight
Price Target: $68
Current: $48.89
Upside: +39.09%
Jan 9, 2026
Initiates: Equal-Weight
Price Target: $17
Current: $15.72
Upside: +8.14%
Nov 5, 2025
Maintains: Overweight
Price Target: $12 → $9
Current: $6.42
Upside: +40.19%
Feb 26, 2025
Maintains: Overweight
Price Target: $110 → $125
Current: $82.18
Upside: +52.11%